Literature DB >> 27867980

C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients.

Dost Sarpel1, Douglas T Dieterich1.   

Abstract

Entities:  

Year:  2016        PMID: 27867980      PMCID: PMC5104607          DOI: 10.21037/atm.2016.09.22

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  22 in total

1.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

2.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

3.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

4.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

5.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

6.  Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Authors:  Vincent Lo Re; Michael J Kallan; Janet P Tate; A Russell Localio; Joseph K Lim; Matthew Bidwell Goetz; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Lesley Park; Robert Dubrow; K Rajender Reddy; Jay R Kostman; Brian L Strom; Amy C Justice
Journal:  Ann Intern Med       Date:  2014-03-18       Impact factor: 25.391

Review 7.  Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening.

Authors:  Dost Sarpel; Esha Baichoo; Douglas T Dieterich
Journal:  Expert Rev Anti Infect Ther       Date:  2016       Impact factor: 5.091

Review 8.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

Authors:  Lucy Platt; Philippa Easterbrook; Erin Gower; Bethan McDonald; Keith Sabin; Catherine McGowan; Irini Yanny; Homie Razavi; Peter Vickerman
Journal:  Lancet Infect Dis       Date:  2016-02-25       Impact factor: 25.071

9.  Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Authors:  Mark Sulkowski; Christophe Hezode; Jan Gerstoft; John M Vierling; Josep Mallolas; Stanislas Pol; Marcelo Kugelmas; Abel Murillo; Nina Weis; Ronald Nahass; Oren Shibolet; Lawrence Serfaty; Marc Bourliere; Edwin DeJesus; Eli Zuckerman; Frank Dutko; Melissa Shaughnessy; Peggy Hwang; Anita Y M Howe; Janice Wahl; Michael Robertson; Eliav Barr; Barbara Haber
Journal:  Lancet       Date:  2014-11-11       Impact factor: 202.731

10.  Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Authors:  Kris V Kowdley; Eric Lawitz; Fred Poordad; Daniel E Cohen; David R Nelson; Stefan Zeuzem; Gregory T Everson; Paul Kwo; Graham R Foster; Mark S Sulkowski; Wangang Xie; Tami Pilot-Matias; George Liossis; Lois Larsen; Amit Khatri; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.